{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T09:12:39Z","timestamp":1694855559702},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Malignant Pleural Mesothelioma (MPM) is rare cancer and has a poor prognosis with resistance to chemotherapy or radiotherapy. Until now there is no standard third-line treatment for patients who have failed second-line therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 58-year-old non-smoking female peasant of ethnic Han was admitted to the oncology department of the 363 Hospital with a primary complaint of chest tightness and breathlessness from 3 months ago.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Positron emission tomography-computed tomography (PET\/CT) examination showed \u201cdirty\u201d pleural and parietal pleural involvement as well as mediastinal and pulmonary hilar lymph node enlargement. Finally, cancer cells were seen after repeated pleural effusion cell examination. Immunohistochemistry confirmed epithelioid of pleural mesothelioma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Apatinib as a third-line treatment after failure from pemetrexed\/cisplatin (PC) as the first-line chemotherapy and gemcitabine\/cisplatin (GP) as the second-line chemotherapy. At first, 250\u200amg\/day was given and 1 week later, the dose was increased to 500\u200amg\/day.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>A 5-month progression-free survival was achieved and toxicity included severe hand-foot syndrome, mild proteinuria, and hypertension.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Apatinib may be a potential therapeutic drug for MPM, particularly as a third-line treatment in cases resistant to chemotherapeutic options.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013105","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T21:26:40Z","timestamp":1541539600000},"page":"e13105","source":"Crossref","is-referenced-by-count":4,"title":["Apatinib for salvage treatment of advanced malignant pleural mesothelioma"],"prefix":"10.1097","volume":"97","author":[{"given":"Zedong","family":"Du","sequence":"first","affiliation":[{"name":"Department of Oncology of 363 Hospital, Cheng Du"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology of 363 Hospital, Cheng Du"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dajun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology of 363 Hospital, Cheng Du, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology of 363 Hospital, Cheng Du"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology of 363 Hospital, Cheng Du"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Oncology of 363 Hospital, Cheng Du"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RongQin","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Oncology of 363 Hospital, Cheng Du"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1183\/09031936.00000811","article-title":"Predicting survival in malignant mesothelioma","volume":"38","author":"Musk","year":"2011","journal-title":"Eur Respir J"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2147\/OTT.S113435","article-title":"Salvage treatment with apatinib for advanced non-small-cell lung cancer","volume":"10","author":"Song","year":"2017","journal-title":"OncoTargets Ther"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/ijc.28829","article-title":"Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"135","author":"Hu","year":"2014","journal-title":"Int J Cancer J Int Cancer"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2147\/OTT.S126471","article-title":"Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report","volume":"10","author":"Deng","year":"2017","journal-title":"OncoTargets and Ther"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2147\/OTT.S126613","article-title":"Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma","volume":"10","author":"Fang","year":"2017","journal-title":"OncoTargets Ther"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.2147\/OTT.S110235","article-title":"Successful treatment of angiosarcoma of the scalp with apatinib: a case report","volume":"9","author":"Ji","year":"2016","journal-title":"OncoTargets Ther"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"20510","DOI":"10.18632\/oncotarget.14724","article-title":"Significant efficacy and well safety of apatinib in an advanced liver cancer patient a case report and literature review","volume":"8","author":"Kou","year":"2017","journal-title":"Oncotarget"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.cllc.2017.03.010","article-title":"LUME-Meso: design and rationale of the phase III part of a placebo-controlled study of nintedanib and pemetrexed\/cisplatin followed by maintenance nintedanib in patients with unresectable malignant pleural mesothelioma","volume":"18","author":"Scagliotti","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"50314","DOI":"10.18632\/oncotarget.18599","article-title":"Advanced alveolar soft part sarcoma responds to apatinib","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pcbi.1005445","article-title":"A computational analysis of in vivo VEGFR activation by multiple co-expressed ligands","volume":"13","author":"Clegg","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"17220","DOI":"10.18632\/oncotarget.7948","article-title":"Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma","volume":"7","author":"Peng","year":"2016","journal-title":"Oncotarget"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo","volume":"102","author":"Tian","year":"2011","journal-title":"Cancer Sci"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2147\/OTT.S119129","article-title":"Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series","volume":"10","author":"Zhang","year":"2017","journal-title":"OncoTargets Ther"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"e3598","DOI":"10.1097\/MD.0000000000003598","article-title":"The use of apatinib in treating nonsmall-cell lung cancer: case report and review of literature","volume":"95","author":"Ding","year":"2016","journal-title":"Medicine"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"42252","DOI":"10.18632\/oncotarget.15036","article-title":"Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"72373","DOI":"10.18632\/oncotarget.12568","article-title":"Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma","volume":"7","author":"Zhou","year":"2016","journal-title":"Oncotarget"},{"key":"R19-20230915","first-page":"887","article-title":"Apatinib for the treatment of gastric cancer","volume":"10","author":"Roviello","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.1158\/0008-5472.CAN-10-0111","article-title":"Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters","volume":"70","author":"Mi","year":"2010","journal-title":"Cancer Res"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.canlet.2016.01.015","article-title":"Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib","volume":"373","author":"Peng","year":"2016","journal-title":"Cancer Lett"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest oncology group study","volume":"25","author":"Garland","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/jclinpath-2013-201609","article-title":"Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA","volume":"66","author":"Henderson","year":"2013","journal-title":"J Clin Pathol"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201811090-00046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:09:28Z","timestamp":1694812168000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201811090-00046"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":23,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013105","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}